OncoMatch/Clinical Trials/NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Is NCT04835584 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including KRT-232 and Dasatinib for chronic myeloid leukemia.
Treatment: KRT-232 · Dasatinib · Nilotinib — This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: TP53 wild-type
Documented TP53wt
Required: BCR ABL1 fusion
BCR-ABL+
Required: ABL1 BCR fusion
BCR-ABL+
Excluded: ABL1 T315I
Known T315I mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: bcr-abl inhibitor
Cannot have received: mdm2 antagonist
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- Georgia Cancer Center at Augusta University · Augusta, Georgia
- University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania
- Texas Oncology- Sammons CC at Baylor · Dallas, Texas
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04835584 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mdm2 antagonist disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 wild-type is a required biomarker for enrollment.
Does this trial require BCR?
Yes, BCR ABL1 fusion is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 BCR fusion is a required biomarker for enrollment.
Are patients with ABL1 alterations eligible?
No. ABL1 T315I is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify